Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 18;22(4):2009.
doi: 10.3390/ijms22042009.

Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases

Affiliations
Review

Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases

Anne Grunenwald et al. Int J Mol Sci. .

Abstract

The incidence of kidney disease is rising, constituting a significant burden on the healthcare system and making identification of new therapeutic targets increasingly urgent. The heme oxygenase (HO) system performs an important function in the regulation of oxidative stress and inflammation and, via these mechanisms, is thought to play a role in the prevention of non-specific injuries following acute renal failure or resulting from chronic kidney disease. The expression of HO-1 is strongly inducible by a wide range of stimuli in the kidney, consequent to the kidney's filtration role which means HO-1 is exposed to a wide range of endogenous and exogenous molecules, and it has been shown to be protective in a variety of nephropathological animal models. Interestingly, the positive effect of HO-1 occurs in both hemolysis- and rhabdomyolysis-dominated diseases, where the kidney is extensively exposed to heme (a major HO-1 inducer), as well as in non-heme-dependent diseases such as hypertension, diabetic nephropathy or progression to end-stage renal disease. This highlights the complexity of HO-1's functions, which is also illustrated by the fact that, despite the abundance of preclinical data, no drug targeting HO-1 has so far been translated into clinical use. The objective of this review is to assess current knowledge relating HO-1's role in the kidney and its potential interest as a nephroprotection agent. The potential therapeutic openings will be presented, in particular through the identification of clinical trials targeting this enzyme or its products.

Keywords: heme; heme-oxygenase-1; hemolysis; ischemia reperfusion; kidney; rhabdomyolysis; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic view of kidney structures describing cortical and medullar compartments, components of glomerular basement membrane and tubular segments and structures. GBM: Glomerular basement membrane, TALH: Thick ascending loop of Henle (Created with BioRender.com).
Figure 2
Figure 2
Renal expression of HO1 (adapted from [27]). HO-1 staining in mouse kidneys in IF (A) and IHC (B). A- HO-1 (red) staining, vWF (green) staining, and colocalization on frozen kidney (x15) sections of mice, injected with PBS (upper panel) or heme as HO1 inducer (lower panel), studied by IF (A); B- HO-1 staining appears in brown on frozen kidneys sections of mice treated with PBS or heme. (C) HO-1 expression in human kidneys: hemosiderin deposits in human kidney biopsies evaluated by Perls’ coloration and HO-1 (brown) staining were performed by IHC. A normal protocol, kidney allograft biopsy performed 3 months after transplant was used as a negative control. Patients 1 and 2 suffered chronic hemolysis associated with prosthetic heart valves, and patient 3 carried the C3 mutation complicated with atypical hemolytic uremic syndrome (arrows indicate glomeruli).
Figure 3
Figure 3
Schematic description of HO-1 regulation in renal pathologies. Plain arrows: proved link, Dotted arrows: suspected link, AKI: acute kidney injury, SCA: sickle cell anemia, HUS: hemolytic uremic syndrom, PNH: paroxysmal nocturnal haemoglobinuria (Created with BioRender.com).

Similar articles

Cited by

References

    1. Jager K.J., Kovesdy C., Langham R., Rosenberg M., Jha V., Zoccali C. A Single Number for Advocacy and Communication—Worldwide More than 850 Million Individuals Have Kidney Diseases. Kidney Int. 2019;96:1048–1050. doi: 10.1016/j.kint.2019.07.012. - DOI - PubMed
    1. Foreman K.J., Marquez N., Dolgert A., Fukutaki K., Fullman N., McGaughey M., Pletcher M.A., Smith A.E., Tang K., Yuan C.-W., et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016–40 for 195 Countries and Territories. Lancet. 2018;392:2052–2090. doi: 10.1016/S0140-6736(18)31694-5. - DOI - PMC - PubMed
    1. Luyckx V.A., Al-Aly Z., Bello A.K., Bellorin-Font E., Carlini R.G., Fabian J., Garcia-Garcia G., Iyengar A., Sekkarie M., van Biesen W., et al. Sustainable Development Goals Relevant to Kidney Health: An Update on Progress. Nat. Rev. Nephrol. 2020 doi: 10.1038/s41581-020-00363-6. - DOI - PMC - PubMed
    1. Cassis P., Zoja C., Perico L., Remuzzi G. A Preclinical Overview of Emerging Therapeutic Targets for Glomerular Diseases. Expert Opin. Ther. Targets. 2019;23:593–606. doi: 10.1080/14728222.2019.1626827. - DOI - PubMed
    1. Ruiz-Ortega M., Rayego-Mateos S., Lamas S., Ortiz A., Rodrigues-Diez R.R. Targeting the Progression of Chronic Kidney Disease. Nat. Rev. Nephrol. 2020;16:269–288. doi: 10.1038/s41581-019-0248-y. - DOI - PubMed

LinkOut - more resources